Breaking News

Synchrony Financial Opens at $23/Share, IPO Priced at $23
Tweet TWEET

ResMed Inc. Announces Exchange Rate For Upcoming Dividend Payment

      ResMed Inc. Announces Exchange Rate For Upcoming Dividend Payment

PR Newswire

SAN DIEGO, Nov. 21, 2012

SAN DIEGO, Nov. 21, 2012 /PRNewswire/ -- ResMed Inc. (NYSE: RMD) today
announced that the dividend to be paid on December 18, 2012, to holders of
Chess Depositary Instruments (CDIs) trading on the Australian Securities
Exchange will be Australian dollar $0.01636 per CDI.

(Logo: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

ResMed previously declared a quarterly dividend of US dollar $0.17 per share,
which had a record date of November 20, 2012, and will be payable on December
18, 2012. The dividend will be paid in US currency to holders of its common
stock trading on the New York Stock Exchange (NYSE).

The dividend paid in Australian currency to CDI holders reflects the exchange
rate on the record date, which was US dollars $1.0389 for each Australian
dollar $1.00, and reflects the 10:1 ratio between CDIs and US common shares
listed on the NYSE.

About ResMed
ResMed is a global leader in the development, manufacturing and marketing of
medical products for the diagnosis, treatment and management of respiratory
disorders, with a focus on sleep-disordered breathing. The company is
dedicated to developing innovative products to improve the lives of those who
suffer from these conditions and to increasing awareness among patients and
healthcare professionals of the potentially serious health consequences of
untreated sleep-disordered breathing. For more information on ResMed, visit
www.resmed.com.

Further information can be obtained by contacting Brett Sandercock at ResMed
Limited, Sydney, on (+612) 8884-2090; or by visiting the Company's
multilingual Website at www.resmed.com.

Statements contained in this release that are not historical facts are
"forward-looking" statements as contemplated by the Private Securities
Litigation Reform Act of 1995. These forward-looking statements, including
statements regarding the Company's future revenue, earnings or expenses, new
product development and new markets for the Company's products, are subject to
risks and uncertainties, which could cause actual results to materially differ
from those projected or implied in the forward-looking statements. Those risks
and uncertainties are discussed in the Company's Annual Report on Form 10-K
for its most recent fiscal year and in other reports the Company files with
the U.S. Securities & Exchange Commission. Those reports are available on the
Company's Website.

SOURCE ResMed Inc.

Website: http://www.resmed.com